Tag: hepatitis C-related liver disease

“Who gets treated for hepatitis C?” is a medical decision for infectious disease specialists, not a question of “ethics, costs or access” for well-meaning executives. “Who pays?” depends on measuring the real social costs of failing to treat a national epidemic and cannot be measured by the limited considerations of private entities and public agencies in a single state, or even several states.